Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Nvidia remains at the heart of the AI ecosystem.
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
Can AI disrupt the software business model?
stocks
Market is misinterpreting AI impact on cheap ASX share
Unwarranted sell-off with shares down by half in three months.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,408.70 | 27.40 | -0.29% |
| CAC 40 | 8,625.84 | 66.77 | 0.78% |
| DAX 40 | 25,293.16 | 117.22 | 0.47% |
| Dow JONES (US) | 49,268.48 | 93.98 | 0.19% |
| FTSE 100 | 10,822.66 | 16.25 | 0.15% |
| HKSE | 26,381.02 | 384.70 | -1.44% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,753.39 | 170.27 | 0.29% |
| NZX 50 Index | 13,670.71 | 138.40 | 1.02% |
| S&P 500 | 6,924.11 | 22.02 | -0.32% |
| S&P/ASX 200 | 9,175.30 | 27.60 | -0.30% |
| SSE Composite Index | 4,146.63 | 0.60 | -0.01% |